Wang Jiayu: Clinical Trials

2 trials sponsored by Wang Jiayu, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 unknown. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Unknown 2

Follow Wang Jiayu: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer
Pegylated Liposomal Doxorubicin + vinorelbine,every cycle is 14d. - Her2-negative Metastatic Breast Cancer, Vinorelbine
Phase 2UnknownWang Jiayu302024-11-012024-10-23
Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer
Eribulin, Bevacizumab - Breast Neoplasms, Neoplasm Metastasis
Phase 2UnknownWang Jiayu602024-08-012024-08-06

Conditions studied

Breast Neoplasms (1)  ·  Neoplasm Metastasis (1)

Interventions

Bevacizumab (1)  ·  Vinorelbine (1)  ·  eribulin (1)  ·  liposomal doxorubicin (1)

Countries

China (1)

Top investigators

Jiayu Wang, doctor (1)

Results publications

PMID 33601296